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Evidence Based Medicine
What is the Role of B-vitamins in stroke prevention in Pakistan?
Maria Khan,1 Emmon Raza,2 Ayeesha Kamran Kamal3
Fellow International Cerebrovascular Translational Clinical Research Training Program, Stroke Service,1 Medical College,2
Stroke Service and Vascular Fellowship Program,3 Aga Khan University Hospital, Karachi, Pakistan.

The VITAmins TO Prevent Stroke-VITATOPS
trial and VITAOPS-DEP trial
Why is this study important?
A person who has had a stroke or transient
ischaemic attack has a higher risk of experiencing similar
major vascular events in the future. This risk remains high
despite aggressive medical and surgical management. An
elevated homocysteine level in plasma is a known risk
factor for major vascular events and it is well established
that daily long-term supplementation with Vitamin B12
and Folic acid lowers these levels by a significant
proportion. The VITATOPS trial was undertaken to test
whether this reduction in homocysteine with vitamin
supplementation translates into actual reduction in
recurrent vascular events in patients with recent stroke
(ischaemic or haemorrhagic) or TIA.
A second add-on substudy (VITATOPS-DEP) was
undertaken on participants from VITATOPS who consented
to additional assessment to analyze the effect of B vitamin
supplementation on depression which is again a very frequent
finding in stroke survivors.

Who were the participants?
A total of 8164 individuals from 123 medical
centers from 20 countries spread across 4 continents
participated in this double-blind, placebo-controlled trial
and were followed for a median duration of 3.4 years. Half
of the included participants were either Southeast or South
Asians. The recruited participants had a documented
stroke or transient ischaemic attack within 7 months prior
to recruitment. Individuals already on Vitamin B or Folic
acid supplementation were excluded. The mean age of the
participants was 62.6 years with a slight male
preponderance.
A total of 563 patients consented to additional
assessment and were included in the VITATOPS-DEP
trial, 284 were in the intervention arm and 279 in the
placebo arm. During the follow-up period ranging from
1-10.5 years, 157 people died and 133 were lost to
follow-up. Therefore for the substudy final analysis was
done on 136 patients in the active arm and 137 in the
placebo arm.
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What was the intervention?
In the main VITATOPS trial 4089 patients were
randomly assigned to the intervention (2 mg folic acid, 25 mg
vitamin B6 and 0.5 mg vitamin B12) and 4075 to control
(placebo pill with same colour and shape) group. Both groups
were comparable in terms of age, gender, ethnicity, stroke
subtypes and comorbidities. VITATOPS-DEP had the same
active drug given to 284 and placebo given to 279
individuals.

What was the outcome?
In VITATOPS, the composite primary outcome of
non-fatal stroke, non-fatal myocardial infarction or vascular
death occurred in 15% of the participants in the intervention
group and in 17% of the patients in the control group (RR
0.91, p=0.05, absolute risk reduction 1.56%). When
evaluated separately, in comparison to placebo, treatment
with daily vitamin B supplement was not associated with a
significant reduction in the relative risk for stroke (p=0.25),
myocardial infarction (p=0.86) or death from any other cause
(p=0.49). A subgroup analysis however, revealed that daily
vitamin B supplementation might actually have a role in
reducing the risk of vascular events in patients with cerebral
small-vessel disease. It was also associated with a significant
reduction in vascular deaths (p=0.04) when compared to
placebo. No adverse effects were encountered in either group.
In the VITATOPS-DEP, primary outcome which was
a major depressive episode occurred in 18.4% of patients in
the intervention arm and 23.3% patients in the placebo arm.
This was a significant difference, translating to a Hazard
Ratio of 0.48 for B vitamins. There was also a non significant
trend towards reduction in the prevalence of major or minor
depression.

What were the conclusions?
The authors concluded that although it is not
associated with any adverse event itself, daily vitamin B
supplementation in stroke/transient ischaemic attack
patients rendered as much future vascular event prevention
as did a placebo. There may be a greater benefit for patients
with small vessel disease.For prevention of a major
depressive episode following stroke, B vitamins now do
have a proven role.
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What impact does this study hold for the
Pakistani patients and practitioners?
Pakistan has a huge number of stroke patients. The
economic burden the management of their disease poses is
tremendous. Current data suggests that patients with a
transient ischaemic attack have a 17% risk of experiencing a
stroke within 6 months. Vigorous therapies which promise to
reduce or delay this risk are indeed welcome. Although
current evidence suggests little role of B vitamins in
prevention of recurrent events except in those with small
vessel disease, they have shown benefit in prevention of
major depression. Thus it is a huge benefit considering that
depression does affect functional and cognitive outcomes
post stroke. Therefore the use of B vitamins particularly in
patients with small vessel lacunar strokes and those with post
stroke depression may be a reasonable, useful and harmless
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therapeutic option.
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